Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders

OBJECTIVE: Our objective was to develop a brief Support Group Leader Self-efficacy Scale (Brief-SGLSS) that maintains the core content and measurement properties of the full 32-item SGLSS among systemic sclerosis (SSc) support group leaders. METHODS: Development and validation involved four steps conducted by researchers and a Support Group Advisory Team of people with SSc: (1) item content assessment and prioritization, including a Delphi process; (2) item analysis and preliminary selection, including analysis of SGLSS measurement properties using Scleroderma Patient-centered Intervention Network-Scleroderma-Support group Leader Education (SPIN-SSLED) trial data and a data-driven item resampling process; (3) advisory team input to select final Brief-SGLSS items; and (4) comparison of convergent validity and trial change data of the Brief-SGLSS and full SGLSS. RESULTS: Items were categorized into six content themes. Two Delphi rounds resulted in one item excluded from consideration. A 6-item Brief-SGLSS was selected at the consensus advisory panel meeting based on the resampling process and content and statistical considerations. The Pearson correlation of the Brief-SGLSS and full SGLSS was 0.96. The standardized mean difference between intervention (n = 74) and waitlist (n = 72) groups in the SPIN-SSLED trial immediately post intervention was 0.93 (95% confidence interval [CI] 0.59-1.27) for the full 32-item SGLSS and 0.93 (95% CI 0.58-1.27) for the Brief-SGLSS. Convergent validity of the Brief-SGLSS and full SGLSS with other measures was similar. CONCLUSION: The 6-item SGLSS is shorter and more feasibly implemented than the full SGLSS and maintains similar measurement properties.

Authors

Institutions

Publication Details

Journal
ACR Open Rheumatology
Published
2026-04-01
DOI
https://doi.org/10.1002/acr2.90027
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders

Sabrina Provencher, Violet Konrad, Laura Dyas, Richard Stuart Henry et al.
ACR Open Rheumatology
Systemic Sclerosis and Related Diseases
article

Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders

Sabrina Provencher, Violet Konrad, Laura Dyas, Richard Stuart Henry, Marie‐Eve Carrier, SPIN‐SSLED Support Group Advisory Team, Brett D. Thombs, Daphna Harel, Marie Hudson
article en

Abstract

OBJECTIVE: Our objective was to develop a brief Support Group Leader Self-efficacy Scale (Brief-SGLSS) that maintains the core content and measurement properties of the full 32-item SGLSS among systemic sclerosis (SSc) support group leaders. METHODS: Development and validation involved four steps conducted by researchers and a Support Group Advisory Team of people with SSc: (1) item content assessment and prioritization, including a Delphi process; (2) item analysis and preliminary selection, including analysis of SGLSS measurement properties using Scleroderma Patient-centered Intervention Network-Scleroderma-Support group Leader Education (SPIN-SSLED) trial data and a data-driven item resampling process; (3) advisory team input to select final Brief-SGLSS items; and (4) comparison of convergent validity and trial change data of the Brief-SGLSS and full SGLSS. RESULTS: Items were categorized into six content themes. Two Delphi rounds resulted in one item excluded from consideration. A 6-item Brief-SGLSS was selected at the consensus advisory panel meeting based on the resampling process and content and statistical considerations. The Pearson correlation of the Brief-SGLSS and full SGLSS was 0.96. The standardized mean difference between intervention (n = 74) and waitlist (n = 72) groups in the SPIN-SSLED trial immediately post intervention was 0.93 (95% confidence interval [CI] 0.59-1.27) for the full 32-item SGLSS and 0.93 (95% CI 0.58-1.27) for the Brief-SGLSS. Convergent validity of the Brief-SGLSS and full SGLSS with other measures was similar. CONCLUSION: The 6-item SGLSS is shorter and more feasibly implemented than the full SGLSS and maintains similar measurement properties.

ACR Open RheumatologyVol. 8(4)
Université de Sherbrooke (CA), Jewish General Hospital (CA), Scleroderma Foundation (US), McGill University (CA), New York University (US)
Canada Research Chairs, Fonds de recherche du Québec, Canadian Institutes of Health Research
Openalex Percentile: Top 31%
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.